Searchable abstracts of presentations at key conferences in endocrinology

ea0077oc5.3 | Bone and Calcium | SFEBES2021

Role of Intact and C-Terminal FGF-23 Assays in the Investigation of Metabolic Bone Disease.

Jethwa Kishan , Bhatti Sumbal , Chipchase Allison , Piec Isabelle , Fraser William , Turner Jeremy

Fibroblast growth factor 23 (FGF-23) is a phosphatonin produced by osteocytes in response to serum phosphate concentration. Immunoassays are widely employed to detect C-terminal fragments of FGF-23 (cFGF-23). Quantitative assays for intact FGF-23 (iFGF-23) measurement are also available. Causes of increased FGF-23 include Tumour Induced Osteomalacia (TIO), X-linked hypophosphataemic rickets (XLH) and end stage renal disease (ESRD). We observed that some individuals, with no id...